We are live on !
Find out more
Logos Global Management Portfolio holdings
AUM
$2.32B
Turnover
52.75%
1-Year Est. Return
536.01%
This Fund
S&P 500
This Quarter Est. Return
+24.5%
1 Year Est. Return
+536.01%
3 Year Est. Return
+1,584.92%
5 Year Est. Return
+2,855.24%
10 Year Est. Return
–
AUM
$2.32B
AUM Growth
+$320M
(+16%)
Cap. Flow
-$21M
Cap. Flow % of AUM
Cap. Flow %
-0.9%
Top 10 Holdings %
Top 10 Hldgs %
48.35%
Holding
91
New
25
Increased
18
Reduced
19
Closed
23
Avg Time Held
Equity + Options
1
year
Top 10 Avg Time Held
Equity + Options
0.9
years
Top 20 Avg Time Held
Equity + Options
0.8
years
Avg Time Held Equity only
1
year
Top 10 Avg Time Held Equity only
0.9
years
Top 20 Avg Time Held Equity only
0.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioNTech
BNTX
|
+$95.5M |
| 2 |
Vera Therapeutics
VERA
|
+$82M |
| 3 |
Celldex Therapeutics
CLDX
|
+$53.3M |
| 4 |
Abivax
ABVX
|
+$39.5M |
| 5 |
Belite Bio
BLTE
|
+$38.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Revolution Medicines
RVMD
|
+$190M |
| 2 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$84.4M |
| 3 |
Terns Pharmaceuticals
TERN
|
+$79.1M |
| 4 |
Cytokinetics
CYTK
|
+$57.7M |
| 5 |
United Therapeutics
UTHR
|
+$47.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.88% |
| 2 | Financials | 0.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Mineralys Therapeutics
MLYS
$1.9B
| $28.3M | 1.22% |
+1,050,000
| New | +$28.8M |
2026 Q2
0 quarters
|
|
27
Replimune Group
REPL
$1.13B
| $27.7M | 1.19% |
+2,500,000
| New | +$15.3M |
2026 Q2
0 quarters
|
|
28
Xenon Pharmaceuticals
XENE
$3.53B
| $27.2M | 1.17% |
450,000
| – | – |
2026 Q1
1 quarter
|
|
29
Structure Therapeutics
GPCR
$1.56B
| $26.8M | 1.16% |
500,000
| – | – |
2023 Q1
13 quarters
|
|
30
Immunovant
IMVT
$6.01B
| $25.6M | 1.1% |
665,000
-410,000
| -38% | -$12.5M |
2022 Q4
14 quarters
|
|
31
Jade Biosciences
JBIO
$948M
| $25M | 1.08% |
1,125,000
+725,000
| +181% | +$15.1M |
2024 Q4
6 quarters
|
|
32
Enliven Therapeutics
ELVN
$3.07B
| $23.6M | 1.02% |
465,000
-75,000
| -14% | -$3.18M |
2023 Q1
13 quarters
|
|
33
Veradermics Inc
MANE
$5.79B
| $22.1M | 0.95% |
180,000
+155,000
| +620% | +$14.5M |
2026 Q1
1 quarter
|
|
34
Avalo Therapeutics
AVTX
$400M
| $21.3M | 0.91% |
1,150,000
+850,000
| +283% | +$13.4M |
2026 Q1
1 quarter
|
|
35
Arcus Biosciences
RCUS
$2.47B
| $20M | 0.86% |
650,000
-550,000
| -46% | -$13.6M |
2026 Q1
1 quarter
|
|
36
Summit Therapeutics
SMMT
$12.4B
| $19.7M | 0.85% |
+1,350,000
| New | +$23.9M |
2026 Q2
0 quarters
|
|
37
Immunocore
IMCR
$1.65B
| $19M | 0.82% |
600,000
-900,000
| -60% | -$26.6M |
2025 Q2
4 quarters
|
|
38
LB Pharmaceuticals
LBRX
$1.27B
| $19M | 0.82% |
585,000
-330,000
| -36% | -$9.7M |
2025 Q3
3 quarters
|
|
39
Minerva Neurosciences
NERV
$115M
| $18.3M | 0.79% |
3,288,777
+73,777
| +2% | +$400K |
2025 Q4
2 quarters
|
|
40
Faeth Therapeutics
FTH
$519M
| $18.1M | 0.78% |
722,020
+692,020
| +2,307% | +$16M |
2026 Q1
1 quarter
|
|
41
CRISPR Therapeutics
CRSP
$4.83B
| $16.4M | 0.7% |
+300,000
| New | +$15.8M |
2026 Q2
0 quarters
|
|
42
DBV Technologies S.A. American Depositary Shares
DBVT
$608M
| $15M | 0.65% |
+915,000
| New | +$17.3M |
2026 Q2
0 quarters
|
|
|
PBLS
43
Parabilis Medicines Inc
PBLS
$3.33B
| $14.4M | 0.62% |
+525,000
| New | +$14.5M |
2026 Q2
0 quarters
|
|
44
Rhythm Pharmaceuticals
RYTM
$6.26B
| $13.9M | 0.6% |
125,000
-325,000
| -72% | -$29.4M |
2025 Q2
4 quarters
|
|
45
Vor Biopharma
VOR
$1.12B
| $12M | 0.52% |
650,000
-100,000
| -13% | -$1.51M |
2025 Q4
2 quarters
|
|
46
Scholar Rock
SRRK
$5.11B
| $11M | 0.47% |
+200,000
| New | +$9.7M |
2026 Q2
0 quarters
|
|
47
Immix Biopharma
IMMX
$692M
| $10.3M | 0.44% |
1,000,000
-225,000
| -18% | -$2.09M |
2025 Q4
2 quarters
|
|
48
Q32 Bio
QTTB
$262M
| $10.2M | 0.44% |
+800,000
| New | +$6.68M |
2026 Q2
0 quarters
|
|
49
Odyssey Therapeutics
ODTX
$917M
| $9.8M | 0.42% |
+521,736
| New | +$9.15M |
2026 Q2
0 quarters
|
|
50
Annexon
ANNX
$722M
| $8.56M | 0.37% |
+1,500,000
| New | +$8.29M |
2026 Q2
0 quarters
|
|
Similar funds
CWM
Logos Global Management's Q2 2026 Portfolio in Review
As of Q2 2026, Logos Global Management held 91 positions worth $2.32B, up 16% from $2B the previous quarter. Its ten largest holdings account for 48% of the portfolio.
Logos Global Management's Q2 2026 filing shows 25 new, 18 increased, 19 reduced and 23 closed positions. Its largest new stake was BioNTech: 1,015,000 shares worth $94.4M. The largest sale was Revolution Medicines, an estimated $190M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 97% a quarter earlier, followed by Financials.
- Logos Global Management's largest Q2 2026 buy was BioNTech: 1,015,000 shares worth $94.4M.
- Logos Global Management added most to Celldex Therapeutics in Q2 2026, an estimated $53.3M increase.
- Logos Global Management's biggest Q2 2026 reduction was Revolution Medicines, cutting an estimated $190M.
- Logos Global Management fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $84.4M.
- Logos Global Management's ten largest holdings make up 48% of its $2.32B portfolio in Q2 2026.
- Logos Global Management opened 25 new positions and closed 23 in Q2 2026.
- Logos Global Management's portfolio value rose 16% quarter-over-quarter to $2.32B.
Based on Logos Global Management's 13F filing for Q2 2026, filed 14 Aug 2026.